Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Well-differentiated Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01845675
What this trial is testing

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Who this might be right for
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Peking Union Medical College Hospital 14
Post-approval studies (Phase 4)Study completedNCT02842749
What this trial is testing

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Who this might be right for
Pancreatic Neuroendocrine Tumors
Novartis Pharmaceuticals 61
Testing effectiveness (Phase 2)Study completedNCT02820857
What this trial is testing

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Who this might be right for
Neuroendocrine Carcinomas
Hospices Civils de Lyon 153
Early research (Phase 1)Ended earlyNCT05605522
What this trial is testing

[225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Cell Carcinoma of Head and NeckColorectal Cancer+4 more
3B Pharmaceuticals GmbH 19
Testing effectiveness (Phase 2)Study completedNCT00121628
What this trial is testing

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Who this might be right for
Thyroid Cancer
Amgen 184
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Early research (Phase 1)UnknownNCT05475210
What this trial is testing

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Molecular Targeting Technologies, Inc. 9
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Testing effectiveness (Phase 2)Looking for participantsNCT07016230
What this trial is testing

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Who this might be right for
Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NEC
Gustave Roussy, Cancer Campus, Grand Paris 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05247905
What this trial is testing

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorUnresectable Pancreatic Neuroendocrine Carcinoma
Alliance for Clinical Trials in Oncology 31
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Large-scale testing (Phase 3)Looking for participantsNCT06937905
What this trial is testing

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 129
Early research (Phase 1)Active Not RecruitingNCT05538130
What this trial is testing

Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Who this might be right for
MelanomaGliomaThyroid Cancer+10 more
Pfizer 148
Testing effectiveness (Phase 2)UnknownNCT01203306
What this trial is testing

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Carcinomas
University of Turin, Italy 42
Testing effectiveness (Phase 2)Study completedNCT00625846
What this trial is testing

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Who this might be right for
Recurrent Thyroid Gland CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v7Stage III Thyroid Gland Medullary Carcinoma AJCC v7+10 more
National Cancer Institute (NCI) 152
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Looking for participantsNCT07080242
What this trial is testing

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Who this might be right for
Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic Neuroendocrine Prostate Cancer+8 more
SystImmune Inc. 120
Testing effectiveness (Phase 2)Ended earlyNCT03630120
What this trial is testing

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, MedullaryDifferentiated Thyroid Cancer+3 more
H. Lee Moffitt Cancer Center and Research Institute 6
Early research (Phase 1)Active Not RecruitingNCT04514497
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Who this might be right for
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine Carcinoma+9 more
National Cancer Institute (NCI) 29
Large-scale testing (Phase 3)WithdrawnNCT04065165
What this trial is testing

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

Who this might be right for
Small Intestinal NETCarcinoid Heart Disease
European Organisation for Research and Treatment of Cancer - EORTC
Next Page